About the Cardiovascular Molecular and Therapeutics Translational Research Group
Heart Disease

About the Cardiovascular Molecular and Therapeutics Translational Research Group

The Cardiovascular Molecular and Therapeutics Translational Research Group aims to increase understanding of molecular mechanisms of advanced heart failure in order to discover new medicines to treat and improve quality of life for patients with this condition.

Easing the Burden of Heart Failure

The prevalence of heart failure is increasing worldwide, increasing the burden on our hospitals, clinicians, communities and families.

Despite best-available treatment options, patients still have a very poor survival rate.

The research by this group is vital to reduce the burden of patients with heart failure and to provide significantly better outcomes for patients.

Highlights for the research group in 2022

In 2022, the group, which has more than nine members, undertook projects that focused on preventing deadly ventricular arrhythmias in heart failure patients. These included the ‘Antiarrhythmic effect of phenytoin in human failing hearts’ study.

Through this research, the group established that phenytoin is able to effectively prevent arrhythmias in a human ventricular model of arrhythmia, using tissue samples from patients with heart failure.

The research group found that it works effectively to prevent arrhythmias in human heart samples from patients who were not receiving Beta-blockers, also spelled β-blockers, (a kind of medicine that slows down a person’s heart activity) at the time of heart transplantation. This is an important result towards providing an additional medicine in this group of patients.

Using phenytoin as a template medicine, the group then designed and synthesised novel compounds. Remarkably, early attempts found some to be more effective than phenytoin at preventing arrhythmias.

At the same time, the group’s ‘Redesigning and optimizing Beta-blocker treatment for patients with heart failure patients’ project, used pharmacological criteria to re-design Beta-blocker use to enable more patients – including those who were previously unable to tolerate Beta-blocker therapy – to take advantage of treatment.

In 2022, the group was also delighted to appoint Dr Kafa Walweel to the group to provide strategic expertise to develop novel antiarrhythmic medicines for patients with heart failure.

Published: November 14, 2023

Related news & events

What are heart arrhythmias?

Heart Disease

What are heart arrhythmias?

Hundreds of thousands of Australians have a heart arrhythmia, but what are heart arrhythmias? Click here to find out more.

Find out more

What is Heart Failure?

Heart Disease

What is Heart Failure?

It’s estimated that around 110,000 Australians live with heart failure, but what exactly is heart failure? Click here to learn more about it.

Find out more

What is Heart Disease?

Heart Disease

What is Heart Disease?

Heart disease is the leading cause of death in Australia. But what exactly is it? In this blog we shed some light on what heart disease is and the most common types.

Find out more

About the Cardiovascular Molecular and Therapeutics Translational Research Group

Heart Disease

About the Cardiovascular Molecular and Therapeutics Translational Research Group

The Cardiovascular Molecular and Therapeutics Translational Research Group aims to increase understanding of molecular mechanisms of advanced heart failure in order to discover new medicines to treat and improve quality of life for patients with this condition. 

Find out more

What is a Research Fellowship?

The Common Good

What is a Research Fellowship?

What is a research fellowship? In this blog, we explain what a research fellowship is and introduce you to our two most recent research fellowship recipients.

Find out more

Giving Day 2023 an Incredible Success

The Common Good

Giving Day 2023 an Incredible Success

Our amazing and generous community have helped exceed our Giving Day goal, with over $157,900 raised!

Find out more

National Safe Work Month 2023

Lung Disease

National Safe Work Month 2023

It’s National Safe Work Month 2023. The theme for this year is ‘For everyone’s safety, work safely.’ Learn more here.

Find out more

Rejuvenation of Wellness Room inside Mental Health Unit

Mental Health

Rejuvenation of Wellness Room inside Mental Health Unit

The wellness room inside The Prince Charles Hospital’s Mental Health Unit has received a welcome rejuvenation thanks to Giving Day support.

Find out more

What is an Allied Health Professional?

Hospital Care

What is an Allied Health Professional?

What is an allied health professional? We answer that frequently asked question and share some examples in this blog.

Find out more